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ABSTRACT 50 
 51 
Background:  Cystic fibrosis (CF), caused by mutations in the gene for the cystic fibrosis 52 
transmembrane conductance regulator gene (CFTR), continues to present diagnostic challenges.  53 
Newborn screening and an evolving understanding of CF genetics have prompted a 54 
reconsideration of the diagnosis consensus criteria.  55 
 56 
Methods:  To improve diagnosis and achieve standardized definitions worldwide, the CF 57 
Foundation convened a committee of 32 experts in CF diagnosis from 9 countries to develop 58 
clear and actionable consensus guidelines on the diagnosis of CF and to clarify diagnostic criteria 59 
and terminology for other disorders associated with CFTR mutations.  An a priori threshold of 60 
≥80% affirmative votes was required for acceptance of each statement.   61 
 62 
Results:  After reviewing relevant literature, the committee convened to review evidence and 63 
cases.  Following the conference, consensus statements were developed by an executive 64 
subcommittee.  The entire consensus committee voted and approved 27 of 28 statements, 7 of 65 
which needed revisions and another round of voting.  66 
 67 
Conclusions:  It is recommended that diagnoses associated with CFTR mutations in all 68 
individuals from newborn to adult be established by evaluation of CFTR function with a sweat 69 
chloride test.  The latest mutation classifications annotated in the CFTR2 project 70 
(http://www.cftr2.org/index.php) should be used to aid in diagnosis.  Newborns with a high 71 
immunoreactive trypsinogen level and inconclusive CFTR functional and genetic testing may be 72 
designated CFTR-related metabolic syndrome (CRMS) or CF Screen Positive, Inconclusive 73 
Diagnosis (CFSPID); these terms are now merged and equivalent, and CRMS/CFSPID may be 74 
used.  ICD-10 codes for use in diagnoses associated with CFTR mutations are included.   75 
 76 
250/250 words    77 
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INTRODUCTION 78 
 79 
Cystic fibrosis (CF) is the most common life-threatening autosomal recessive disease in the 80 
United States, affecting approximately 1 in 4000 newborns in the United States,1–3 and occurring 81 
at higher frequencies in some European countries.4,5  Cystic fibrosis is a multisystem disorder 82 
caused by mutations in the gene for the cystic fibrosis transmembrane conductance regulator 83 
(CFTR), which encodes and ion channel protein,6 with more than 2000 mutations identified to 84 
date (http://www.genet.sickkids.on.ca/cftr/app7).  85 
 86 
A diagnosis of CF initially relied on phenotype, with clinical recognition of characteristic signs 87 
and symptoms.8  (See also Addendum for J Pediatrics Manuscript (MS) #6, which is being 88 
drafted.)  However, due to widespread CF newborn screening (NBS), at least 64% of new CF 89 
diagnoses in the United States now occur in asymptomatic or minimally symptomatic infants 90 
following a positive NBS result.9  Although the majority of these screen-positive infants can be 91 
readily diagnosed with CF after a confirmatory test showing high sweat chloride concentration, 92 
the diagnosis is not clear in some individuals,10,11 leading to persistent challenges12 and stresses, 93 
and importantly including a potentially disturbed parent/child relationship.13–15  Furthermore, 94 
universal NBS was implemented only recently in the United States, and many individuals born 95 
there prior to 2010 have not been screened.  Diagnosis of CF in the nonscreened population can 96 
be challenging, because the age of onset and severity of symptoms as a result of CFTR 97 
dysfunction can be highly variable.  Symptoms can include subtle presentations of pancreatitis or 98 
respiratory symptoms in older children and adults, nasal polyposis, and male infertility).16–18  99 
(See also Addendum for J Pediatrics MS #6, which is being drafted.)   100 
 101 
The last few years have seen significant growth of phenotypic and genotypic information on CF 102 
that can help with interpretation of the disease status in many of these patients.  International 103 
collection of clinical data from individuals with CF19 and laboratory advances20 provide 104 
functional insight into the physiological impact of the most common mutations (see Addendum 105 
for J Pediatrics MS #3, which is being drafted).  Due to this new information, and to seek 106 
harmony with the diagnostic criteria and terminology21 of the European Cystic Fibrosis Society 107 
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(ECFS), it was decided that the 2008 diagnostic guidelines22 of the Cystic Fibrosis Foundation 108 
(CF Foundation) should be revised.  109 
 110 
The CF Foundation convened a committee of 32 experts in the diagnosis of CF from nine 111 
countries to update diagnostic guidance and achieve standardization in definitions worldwide.  112 
The mission of this committee was to develop clear and actionable consensus guidelines on 113 
diagnosis of CF and other conditions associated with mutations in the CFTR gene such as CFTR-114 
related metabolic syndrome (CRMS)23 or CF Screen Positive, Inconclusive Diagnosis 115 
(CFSPID),24 and CFTR-related disorder.25  The recommendations in this document address 116 
individuals with both clear and unclear diagnosis, including infants with positive NBS and/or 117 
prenatal diagnosis (see Addendum for J Pediatrics MS #4, which is being drafted), and 118 
individuals with CF-like symptoms who were either never screened or who had false negative 119 
newborn or prenatal screening results (see Addendum for J Pediatrics MS #6, which is being 120 
drafted).  Case studies, designed to show how the recommendations should be applied in 121 
challenging clinical scenarios, can be found in additional manuscripts created as a result of this 122 
conference, published as Supplement X of The Journal of Pediatrics (see Addendum for J 123 
Pediatrics MS #3-#6). 124 
 125 
 126 
METHODS 127 
 128 
An international consensus committee of 32 experts was purposively selected and tasked with 129 
the development of guidelines on the diagnosis of CF.  Committee selection was determined to 130 
include participants representative of worldwide CF care communities, particularly pediatric 131 
CF providers with NBS experience, and other relevant specialists including adult CF providers.  132 
The committee first reviewed the existing CF Foundation diagnosis guidelines,22 a list of 133 
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publications on CF diagnosis published since the 2008 CF Foundation Diagnosis Guidelines, 134 
and 10 articles selected by conference co-chairs.  An executive subcommittee consisting of 10 135 
representatives from 4 countries was established prior to the October 2015 North American CF 136 
Conference (NACFC). 137 
 138 
The consensus conference was held prior to the 2015 NACFC.  At this conference, the 139 
committee presented and discussed new studies and data on CF diagnosis.  An executive 140 
subcommittee developed the consensus statements at subsequent meetings.  These statements 141 
were reviewed by the consensus committee and voted on by the members using an electronic 142 
survey tool (SurveyMonkey).26  Individuals voting against a statement were asked to provide a 143 
revised statement or explanation.  An a priori threshold of ≥ 80% affirmative votes was 144 
required for acceptance.  Statements that did not reach 80% agreement with the associated 145 
committee feedback were reviewed by the committee co-chairs and revised with input from the 146 
rest of the executive subcommittee. 147 
 148 
After the recommendation statements were agreed upon, they were presented to the European 149 
CF Society (ECFS) at the Diagnostic Network Working Group annual meeting in February 150 
2016 to help engage all parties in the discussion.  The manuscript was distributed for feedback 151 
from the executive subcommittee, conference committee, the CF Foundation’s CF Center 152 
Committee, all the CF centers in the United States, parents of screened infants, and to a variety 153 
of international organizations and their members for a public comment period.  154 
 155 
RESULTS AND DISCUSSION 156 
 157 
In the survey, participants were able to vote in agreement, disagreement, or to abstain.  One 158 
committee member did not participate in this vote.  Of the 28 statements initially voted on, 8 159 
did not reach at least 80% agreement.  The 8 statements that did not pass were reviewed and 160 
revised, and reduced to seven statements by the chairs and the executive committee and sent 161 
out for a second round of voting.  All but one of the 32 committee members participated in this 162 
vote.  All 7 of the revised statements passed in the second round of voting.  For additional 163 
detail and a historical perspective please see other articles in the supplement.   164 
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 165 
The committee approved 27 consensus statements (Table I) in 4 overlapping categories that 166 
apply to:  167 
1. Both screened and nonscreened populations;  168 
2. Screened pediatric populations, ie, fetuses undergoing prenatal testing and neonates; 169 
3. Infants with uncertain diagnosis and designated either CRMS or CFSPID (now 170 
considered to be the same) 171 
4. Patients presenting clinically who represent nonscreened populations, including children 172 
born at home or in regions before NBS implementation, those with false negative 173 
screening tests, and older individuals.  174 
 175 
The Figure provides a simplified algorithm for how these consensus statements should be 176 
applied to individuals under suspicion of CF.  Even though many individuals enter this algorithm 177 
through a positive newborn screen in which CFTR genetic testing was done, the diagnosis of CF 178 
is primarily based on the demonstration of abnormal CFTR function by measurement of chloride 179 
concentration in the sweat.22  Although obtaining an adequate sweat specimen for chloride 180 
measurements can be challenging, particularly in very young infants, experience and studies 181 
have shown that this is feasible in full-term infants during the first postnatal month, ie, during the 182 
neonatal period.27–30  Following the committee’s recommendations, shown below, will improve 183 
reliability of the result.   184 
 185 
1. All Populations:  Sweat chloride testing should be performed according to approved 186 
procedural guidelines published in established, international protocols such as the CLSI 187 
2009 Guidelines.  188 
Following appropriate protocols for performing the sweat test28 is important for achieving 189 
accurate results and minimizing collection of inadequate amounts of sweat (quantity not 190 
sufficient, QNS).29–33  (See also Addendum for J Pediatrics MS #4, which is being drafted.)  191 
 192 
2. For Newborns:  Newborns with a positive CF newborn screen, to increase the 193 
likelihood of collecting an adequate sweat specimen, should have the test performed 194 
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bilaterally and when the infant weighs > 2 kg, and is at least 36 weeks of corrected 195 
gestational age. 196 
Sweat samples collected bilaterally must not be combined; rather, they should be 197 
analyzed separately, providing a useful quality control measure.29   198 
 199 
3. For Newborns:  Newborns greater than 36 weeks gestation and 2 kg body weight 200 
with a positive CF newborn screen, or positive prenatal genetic test, should have 201 
sweat chloride testing performed as soon as possible after 10 days of age, ideally by 202 
the end of the neonatal period (4 weeks of age). 203 
Timing of the sweat chloride test is crucial in newborns.34  Sweat testing can occur as 204 
early as 48 hours after birth,25 but most NBS results will not be available by that time.  205 
However, testing should occur before the end of the neonatal period because malnutrition 206 
and other risks such as dehydration may be present even in the first few weeks of life.35–38 207 
 208 
4. For Newborns:  In infants with presumptive CF identified through NBS, CF 209 
treatment should not be delayed while efforts to establish a diagnosis of CF are 210 
initiated. 211 
Optimal outcomes depend on early intervention.  Efforts to obtain adequate quantities of 212 
sweat and accurate sweat chloride values should not delay start of salt supplementation or 213 
other appropriate therapies.39  The CF Foundation recommends that infants with CF have 214 
an initial visit at an accredited CF care center within 24-72 hours of diagnosis,39 and 215 
timing of the initial visit for infants with a presumptive diagnosis should aim to meet this 216 
timeframe.  A presumptive diagnosis of CF for purposes of treatment initiation can 217 
include the following clinical circumstances: 218 
 A positive CF newborn screen showing 2 CF-causing CFTR mutations (see 219 
below) 220 
 A positive CF newborn screen AND clinical signs and symptoms of CF  221 
 Meconium ileus, with or without a positive newborn screen. 222 
However, definitive diagnosis requires demonstration of CFTR dysfunction.  223 
 224 
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5. All Populations:  Sweat chloride analysis should be performed within a few hours of 225 
sweat collection and the results and interpretations should be reported to clinicians and 226 
parents or patients, as soon as possible and certainly on the same day. 227 
Prompt reporting should be made regardless of sweat test results.40–43  A second, confirmatory, 228 
sweat test is not necessary, nor is it likely to be reimbursable; this is a change from previous CF 229 
Foundation diagnostic guidelines.22,44 230 
 231 
SWEAT CHLORIDE TEST RESULTS ≥ 60 MMOL/L 232 
6. All Populations:  In individuals presenting with a positive newborn screen, clinical 233 
features consistent with CF, or a positive family history, a diagnosis of CF can be made if 234 
the sweat chloride value is ≥ 60 mmol/L. 235 
While the sweat test is commonly used for diagnosis of individuals presenting with symptoms of 236 
CF, many newborns are reported as having CF based solely on a positive NBS result.  However, 237 
NBS tests must always be considered screening procedures and not diagnostic studies. The 238 
genetic analysis included as part of many NBS programs must not be relied upon for conclusive 239 
diagnosis, as errors can arise from problems with the Guthrie card,45 changes in the mutation 240 
panel utilized by the NBS program (for example, see ref. 46), or detection of 2 CFTR mutations 241 
in cis (ie, on the same chromosome).47  (See also Addendum for J Pediatrics MS #3, which is 242 
being drafted.) 243 
 244 
7. For Newborns:  Individuals who are screen-positive and meet sweat chloride 245 
criteria for CF diagnosis should undergo CFTR genetic testing if the CFTR genotype 246 
was not available through the screening process or is incomplete. 247 
Genetic testing is an important part of the diagnostic work-up, and it is not uncommon for 248 
a positive NBS result to include the recognition of 2 CF-causing mutations.  The 249 
screening result should be confirmed in a clinical genetics laboratory, even if a sweat 250 
chloride result is positive. The genetic testing results now have additional value in 251 
therapy selection.48  252 
 253 
SWEAT CHLORIDE TEST RESULTS ≤ 29 MMOL/L 254 
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8. For Newborns:  In individuals with a positive newborn screen, a sweat chloride of 255 
less than 30 mmol/L indicates that CF is unlikely. 256 
 257 
9. All Populations:  Individuals with clinical features that may be consistent with CF who 258 
have a sweat chloride less than 30 mmol/L indicates that CF is less likely.  It may however 259 
be considered if evolving clinical criteria and/or CFTR genotyping support CF and not an 260 
alternative diagnosis. 261 
Note that the upper limit for a normal sweat chloride is 29 mmol/L for all age groups.  This is a 262 
change from previous guidelines for people > 6 months of age (the previous upper limit of 263 
normal was 39 mmol/L).   264 
 265 
See Addendum for J Pediatrics MS #3 (which is being drafted) for more details regarding the 266 
diagnosis of CF in the very rare individual with sweat chloride ≤29 mmol/L.19  Some CFTR 267 
mutations, such as c.3717+12191C>T (legacy name 3849+10kb C->T), are associated with low 268 
sweat chloride values; in these cases an alternative diagnosis does not need to be ruled out.49,50  269 
(See also Addendum for J Pediatrics MS #6, which is being drafted.) 270 
 271 
SWEAT CHLORIDE TEST RESULTS OF 30-59 MMOL/L 272 
10. All Populations:  Individuals presenting with a positive newborn screen, symptoms of 273 
CF, or a positive family history, and sweat chloride values in the intermediate range (30-59 274 
mmol/L) on two separate occasions may have CF.  They should be considered for extended 275 
CFTR gene analysis and/or CFTR functional analysis. 276 
Individuals with sweat chloride concentrations in the intermediate range will need further study 277 
to establish or rule out a CF diagnosis.11,51,52  Evidence may be provided by CFTR genotype.19  278 
(See Addendum for J Pediatrics MS #3, which is being drafted to discuss CFTR genetic testing 279 
and interpretation in detail) or by further CFTR physiologic testing.53–56  For discussion of 280 
demonstration of CFTR dysfunction including the use of nasal potential difference (NPD) or 281 
intestinal current measurement (ICM) on the screen-positive newborn see Addendum for J 282 
Pediatrics MS #4, which is being drafted; see MS #6 for information on the symptomatic 283 
patient).   284 
 285 
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NEXT STEPS FOR INTERMEDIATE SWEAT TEST RESULTS 286 
11. All Populations:  The latest classifications identified in the CFTR2 project 287 
[http://www.cftr2.org/index.php] should be used to aid with CF diagnosis: 288 
 CF-causing mutation: Individuals with 2 copies on separate alleles will likely have 289 
CF (clinical sweat confirmation needed) 290 
 Mutation of varying clinical consequence (MVCC): a mutation that in combination 291 
with a CF-causing mutation or another MVCC mutation may result in CF 292 
 Uncharacterized mutation/mutation of unknown clinical consequence (UNK): 293 
mutation that has not been evaluated by CFTR2 and may be disease-causing or of 294 
variable clinical consequences or benign 295 
 Non-CF causing mutation: individuals with 1 or more are unlikely to have CF (as a 296 
result of that allele) 297 
The Clinical and Functional Translation of CFTR (CFTR2) project provides a definitive 298 
characterization of CFTR mutations by collecting clinical and laboratory evidence of phenotypic 299 
consequence.19  For each mutation, the CFTR2 website provides information and classification 300 
as listed above.  The CFTR2 project is updated as mutation functional analyses are completed.  301 
Because mutation categorization may change over time, it is important to confirm genotype 302 
interpretation on the most current version of the website. 303 
 304 
12. All Populations:  In individuals presenting with a positive newborn screen, symptoms of 305 
CF, or a positive family history, the identification of 2 CF-causing mutations (defined by 306 
CFTR2) is consistent with a diagnosis of CF.  Sweat chloride testing is necessary, though, to 307 
confirm the diagnosis. 308 
As stated above, there are situations in which repeated sweat chloride testing does not provide 309 
further clarity, such as in individuals with CFTR mutations known to be associated with a normal 310 
sweat chloride.49,50  (See Addendum for J Pediatrics MS #3, which is being drafted, for further 311 
exploration of this topic).  312 
 313 
13. All Populations:  The absence of detection of 2 CF-causing CFTR mutations does not 314 
exclude a diagnosis of CF.  315 
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Because classification and identification of CF-causing CFTR mutations is ongoing, there are 316 
individuals with CF in whom 2 CFTR mutations have not been detected.  Thus, while the CFTR2 317 
initiative has been a valuable step forward in improving the diagnostic characterization of 318 
patients with CFTR mutations, it does not take the place of clinical observation and expertise.  319 
(See Addendum for J Pediatrics Manuscripts #3, #5, and #6, being drafted for more in-depth 320 
discussion.) 321 
 322 
To further explore a CF diagnosis in individuals with a positive newborn screen, symptoms of 323 
CF, or a positive family history, intermediate sweat chloride values (30-59 mmol/L) and fewer 324 
than 2 CF-causing mutations, the committee recommends additional CFTR physiological testing.  325 
Clinical electrophysiological tests that directly measure CFTR function, such as NPD and ICM 326 
may be useful to confirm a diagnosis of CF.57 327 
 328 
14. All Populations:  If further CF functional testing is needed (NPD and ICM), it should 329 
be performed in a validated reference center with trained staff certified by the CF 330 
Foundation Therapeutics Development Network (TDN) or ECFS Clinical Trial Network 331 
(CTN). 332 
When performed correctly, NPD can discriminate between a wide range of CFTR function.58–60  333 
ICM can be used to confirm a diagnosis of CF in the context of intermediate sweat chloride 334 
levels,55,56,60–63 and may be useful when NPD testing is unsuccessful (for example, when 335 
attempting to conduct NPD testing in the uncooperative child).64  (See also Addendum for J 336 
Pediatrics MS #4, which is being drafted.)  337 
 338 
15. For Newborns:  In individuals with a positive newborn screen but variable or 339 
uncharacterized CFTR mutations (<2 CF-causing mutations), the diagnosis of CF 340 
can be made by demonstrating CFTR dysfunction (a sweat chloride > 60 mmol/L or 341 
CF-typical NPD or ICM). 342 
 343 
FOR THE NEWBORN WITH AN INCONCLUSIVE DIAGNOSIS 344 
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16. For Newborns:  The term CRMS is used in the United States for health care 345 
delivery purposes and CFSPID is used in other countries, but these both describe an 346 
inconclusive diagnosis following NBS. 347 
Newborn infants with a high level of immunoreactive trypsinogen (IRT) and inconclusive 348 
CFTR functional and genetic testing may be labelled either CRMS23 or CFSPID.24  (See 349 
also Addendum for J Pediatrics MS #5, which is being drafted.)  CFSPID describes the 350 
inconclusive nature of the condition in a manner that is easy for patients and families to 351 
understand and can be designated by ICD-10 code P09.  However, due to US health care 352 
system requirements (see Addendum for J Pediatrics MS #2, which is being drafted), 353 
CRMS (ICD-10 code E88.89) must be used in clinical settings of the USA for continuing, 354 
follow-up care.  These two terms are nearly identical, and the Consensus Committee 355 
recommends that the two terms be harmonized, for improved international 356 
communications and analysis of clinical outcomes.  The term CRMS/CFSPID will be 357 
used throughout this supplement and is recommended.65   358 
 359 
17. For Newborns:  The term CRMS/CFSPID is reserved for screen-positive 360 
individuals without clinical features consistent with a diagnosis of CF. 361 
The CRMS/CFSPID diagnosis should not be used in other clinical scenarios, including 362 
those involving individuals who have not received a positive NBS result, or individuals 363 
who have clinical symptoms attributable to CFTR dysfunction (see Addendum for J 364 
Pediatrics MS #6, which is being drafted).   365 
 366 
18. For Newborns:  The definition of CRMS/CFSPID is an infant with a positive 367 
NBS test for CF and either:  368 
 A sweat chloride value less than 30 mmol/L and 2 CFTR mutations, at least 1 369 
of which has unclear phenotypic consequences  370 
OR  371 
 An intermediate sweat chloride value (30-59 mmol/L) and 1 or 0 CF-causing 372 
mutations 373 
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Individuals designated as CRMS/CFSPID should be seen at an accredited CF care center 374 
to ensure there are no hidden signs or symptoms of CF and to establish a plan for 375 
follow-up.23,66  376 
 377 
NEXT STEPS IN THE NEWBORN WITH CRMS/CFSPID DESIGNATION  378 
(For detailed information see Addendum for J Pediatrics MS #5.) 379 
19. For Newborns:  Children designated as CRMS/CFSPID should undergo at least 380 
one repeat sweat chloride test at CF centers with suitable expertise, such as an 381 
accredited CF center. 382 
This test should be used to confirm the CRMS/CFSPID designation.  Appropriate timing 383 
for the repeat sweat chloride test is discussed in J Pediatrics MS #5 (being drafted; see 384 
Addendum). 385 
 386 
20. For Newborns:  Children designated as CRMS/CFSPID should have clinical 387 
evaluation performed by CF providers to identify the minority that may develop 388 
clinical symptoms. 389 
 390 
21. For Newborns:  Children designated as CRMS/CFSPID can be considered for 391 
extended CFTR gene analysis (sequencing and or deletion duplication testing), as 392 
well as CFTR functional analysis (NPD/ICM) testing to further define their 393 
likelihood of developing CF. 394 
 395 
22. For Newborns:  The decision to reclassify children designated as CRMS/CFSPID 396 
as CF is an integrated decision that should take into account functional assessment 397 
of CFTR (sweat chloride, and possibly NPD/ICM), CFTR genetic analysis, and 398 
clinical assessment by the CF clinicians caring for the patient. 399 
The decision to change a designation from CRMS/CFSPID to CF is a difficult one and 400 
should be made by an experienced CF physician.23,24  (See also Addendum for J 401 
Pediatrics MS #5, which is being drafted.)  Monitoring symptoms, surveillance 402 
evaluations (respiratory tract cultures, imaging, and spirometry or lung-clearance index 403 
when age-appropriate), and measuring fecal elastase levels or following IRT or 404 
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pancreatitis associated protein (PAP) trends may be considered if clinically indicated and 405 
to objectively identify CF clinical manifestations (phenotypes).10,23,54,56,66–68  CF cannot 406 
be diagnosed through the identification of elevated levels of IRT, which can occur in the 407 
context of other tissue stress.69,70 408 
  409 
23. For Newborns:  Genetic counseling should be offered to families of individuals 410 
followed for CRMS/CFSPID, including a discussion of the risk in future 411 
pregnancies. 412 
Our understanding of the impact of various CFTR mutations is evolving and will 413 
continue to be clarified for many years.  Genetic counseling is important for parents to 414 
understand the risk of a child having CF or being designated as CRMS/CFSPID in future 415 
pregnancies.23,24 416 
 417 
24. For Newborns, Research Recommendation:  Infants with a designation of 418 
CRMS/CFSPID (by definition) do not have clinical features consistent with a 419 
diagnosis of CF and further research is needed to determine the prognosis and best 420 
practices for frequency and duration of follow up. 421 
There is inadequate evidence to recommend a standard period and frequency for follow-422 
up of these individuals.  Further research on this will require common definitions, and the 423 
merging of CRMS and CFSPID designations is therefore especially timely. 424 
 425 
GENERAL NOTE FOR THE NONSCREENED INDIVIDUAL  426 
25. For individuals presenting with CF symptoms, the same diagnostic criteria 427 
recommended for the screened population for sweat chloride testing, CFTR genetic 428 
analysis, and CFTR functional testing should be used to confirm a CF diagnosis. 429 
Although NBS encompasses the majority of new diagnoses, diagnosis of CF in the nonscreened 430 
population, particularly those born before the initiation of NBS at all accredited CF centers, still 431 
occurs.  In these individuals, the diagnostic algorithm (Figure) remains applicable.  However, 432 
the assignment of a diagnosis of CF will be weighed against alternative diagnostic explanations 433 
of the presenting symptom or feature.  Therefore, the pre-test probability will influence the 434 
interpretation of sweat chloride testing, CFTR genetic analysis, or CFTR physiologic testing.  435 
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Definitive diagnostic criteria for nonscreened populations include the presence of CF symptoms 436 
OR a family history and: 437 
 Sweat chloride > 60 mmol/L 438 
OR 439 
 The presence of 2 CF-causing CFTR mutations 440 
OR 441 
 Physiologic testing demonstrating CFTR dysfunction.  442 
The diagnosis of CF can also be appropriate if the above testing is not definitive, but CFTR 443 
dysfunction is the best explanation of the patient’s symptoms, and CF therapies would improve 444 
the patient’s condition.  445 
 446 
FOR THE NONSCREENED INDIVIDUAL WITH THE INCONCLUSIVE DIAGNOSIS 447 
There are scenarios in which a given patient may not meet the above diagnostic criteria to be 448 
diagnosed with CF, but also cannot be “ruled-out” as not having CF.  Though this situation is 449 
similar to infants with CRMS/CFSPID, those classifications are not appropriate for the 450 
nonscreened populations.   451 
 452 
26. The diagnosis of CFTR-related disorder has been defined as a monosymptomatic 453 
clinical entity [CBAVD/pancreatitis/bronchiectasis] associated with CFTR dysfunction that 454 
does not fulfill the diagnostic criteria for CF.  455 
Individuals with a monosymptomatic CFTR-related disorder25 should be assessed and followed 456 
by a CF physician.  (See Addendum for J Pediatrics MS #6, which is being drafted.)  457 
 458 
27. Clinicians should avoid the use of terms like classic/nonclassic CF, typical/atypical CF, 459 
delayed CF, since these terms have no harmonized definition and could be confusing for 460 
families or caregivers. 461 
In these and other situations, education on clinical entities and organ pathologies associated with 462 
CF and their relationship with CFTR-related disorder, should be provided to patients, families, 463 
and primary care providers to aid in the early recognition of symptoms of CF. 464 
 465 
ICD-10 CODES FOR INDIVIDUALS WITH CFTR DYSFUNCTION 466 
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The International Statistical Classification of Diseases and Related Health Problems (ICD)71 467 
system is a medical classification list created collaboratively by the World Health Organization 468 
(WHO) to be “the international standard for defining and reporting diseases and health 469 
conditions.  It allows the world to compare and share health information using a common 470 
language.”72  It is an alphanumeric system containing codes for diseases, signs and symptoms, 471 
abnormal findings, complaints, social circumstances, and external causes of injury or diseases.  472 
The ICD system is valuable, indeed essential, for many purposes including:  1) entry and 473 
continuation into the healthcare delivery mechanisms of some countries such as the United States 474 
where the ICD codes are an integral and required component of billing; 2) coding death 475 
certificates internationally, thus allowing assessment of mortality data; 3) epidemiologic 476 
research; and 4) medical economics research.  477 
 478 
The most recent revision of the system, ICD-10, implemented in October 2015, provides more 479 
than 14,400 different codes and can be expanded to over 16,000 codes by using optional sub-480 
classifications.  It is not possible to convert ICD-9 datasets to ICD-10.  In the ICD-10 coding 481 
system, characters 1-3 indicate the category of disease; 4-6 indicate etiology, anatomic site, 482 
severity or other clinical detail of disease; and character 7 is a placeholder for extending the code 483 
to increase specificity.  The designation “E” indicates endocrine, nutritional and metabolic 484 
diseases, while “J” applies to diseases of the respiratory system.   485 
 486 
Some CF specialists were engaged in the ICD-10 development process but the degree of 487 
influence was limited, and coding for diseases or disorders caused by CFTR dysfunction is not 488 
ideal, including the absence of a code for CFTR-related disorder (CFTR-RD).  The current ICD-489 
10 code is undergoing revision to ICD-11, which is due to be completed in 2018.  Participation is 490 
invited (http://www.who.int/classifications/icd/revision/en/), and we encourage involvement by 491 
CF caregivers.   492 
 493 
A list of ICD-10 codes that should be used in the delivery of care for those disorders associated 494 
with CFTR mutations (that is, CF, CRMS/CFSPID, and CFTR-related disorder) is shown in 495 
Table II.  496 
 497 
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CONCLUSION 498 
 499 
Although newborn screening is now widely implemented, the diagnosis of CF is not always 500 
clear.  A sweat test is required for confirmation of CF; a sweat chloride level > 60 mmol/L 501 
indicates a diagnosis of CF and a sweat chloride level < 30 mmol/L indicates that CF is unlikely.  502 
In individuals who fall into the intermediate sweat chloride level, 30-59 mmol/L, genetic 503 
analysis is required. Further testing for CFTR function such as NPD and ICM may also be 504 
indicated but need to be performed in a specialized center approved for such studies.  Some 505 
individuals with sweat chloride levels from 30-59 mmol/L or even ≤ 29 mmol/L and 506 
inconclusive genetic testing may also be designated as CRMS/CFSPID due to the results of 507 
NBS, but further research is needed to determine their prognosis, best practice, and frequency of 508 
follow-up.  509 
 510 
Table I: Consensus Recommendations for Diagnosis of Cystic Fibrosis 511 
 Statements Vote Abstain (n) 
1 Sweat chloride testing should be performed according to 
approved procedural guidelines published in established, 
international protocols such as the CLSI 2009 Guidelines. 
100% 0 
2 Newborns with a positive CF newborn screen, to increase the 
likelihood of collecting an adequate sweat specimen, should 
have the test performed bilaterally and when the infant weighs > 
2 kg, and is at least 36 weeks of corrected gestational age. 
87% 0 
3 Newborns greater than 36 weeks gestation and 2 kg body weight 
with a positive CF newborn screen, or positive prenatal genetic 
test, should have sweat chloride testing performed as soon as 
possible after 10 days of age, ideally by the end of the neonatal 
period (4 weeks of age). 
93% 1 
4 In infants with presumptive CF identified through NBS, CF 
treatment should not be delayed while efforts to establish a 
diagnosis of CF are initiated. 
83% 1 
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5  Sweat chloride analysis should be performed within a few hours 
of sweat collection and the results and interpretations should be 
reported to clinicians and parents or patients, as soon as possible 
and certainly on the same day. 
90% 0 
6 In individuals presenting with a positive newborn screen, 
clinical features consistent with CF, or a positive family history, 
a diagnosis of CF can be made if the sweat chloride value is ≥ 
60 mmol/L. 
93% 0 
7 Individuals who are screen-positive and meet sweat chloride 
criteria for CF diagnosis should undergo CFTR genetic testing if 
the CFTR genotype was not available through the screening 
process or is incomplete. 
100% 0 
8 In individuals with a positive newborn screen, a sweat chloride 
of less than 30 mmol/L indicates that CF is unlikely. 
82% 2 
9 Individuals with clinical features that may be consistent with CF 
who have a sweat chloride less than 30 mmol/L indicates that 
CF is less likely. It may however be considered if evolving 
clinical criteria and/or CFTR genotyping support CF and not an 
alternative diagnosis. 
80% 0 
10 Individuals presenting with a positive newborn screen, 
symptoms of CF, or a positive family history, and sweat 
chloride values in the intermediate range (30-59 mmol/L) on 
two separate occasions may have CF. They should be 
considered for extended CFTR gene analysis and/or CFTR 
functional analysis. 
90% 0 
11 The latest classifications identified in the CFTR2 project 
[http://www.cftr2.org/index.php] should be used to aid with CF 
diagnosis: 
 CF-causing mutation: Individuals with 2 copies on separate 
alleles will likely have CF (clinical sweat confirmation 
needed) 
100% 0 
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 Mutation of varying clinical consequence (MVCC): a 
mutation that in combination with a CF-causing mutation or 
another MVCC mutation may result in CF 
 Uncharacterized mutation/mutation of unknown clinical 
consequence (UNK): mutations that have not been evaluated 
by CFTR2 and may be disease-causing or of variable clinical 
consequences or benign 
 Non-CF causing mutation: individuals with 1 or more are 
unlikely to have CF (as a result of that allele) 
12 In individuals presenting with a positive newborn screen, 
symptoms of CF, or a positive family history, the identification 
of 2 CF-causing mutations (defined by CFTR2) is consistent 
with a diagnosis of CF. Sweat chloride testing is necessary, 
though, to confirm the diagnosis. 
87% 0 
13 The absence of detection of 2 CF-causing CFTR mutations does 
not exclude a diagnosis of CF. 
93% 1 
14 If further CF functional testing is needed (NPD and ICM), it 
should be performed in a validated reference center with trained 
staff certified by the CF Foundation Therapeutics Development 
Network (TDN) or ECFS Clinical Trial Network (CTN). 
100% 0 
15 In individuals with a positive newborn screen but variable or 
uncharacterized CFTR mutations (<2 CF-causing mutations), 
the diagnosis of CF can be made by demonstrating CFTR 
dysfunction (a sweat chloride > 60 mmol/L or CF-typical NPD 
or ICM). 
93% 0 
16 The term CRMS is used in U.S. for health care delivery 
purposes and CFSPID is used in other countries, but these both 
describe an inconclusive diagnosis following NBS. 
96% 2 
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17 The term CRMS/CFSPID is reserved for screen- positive 
individuals without clinical features consistent with a diagnosis 
of CF. 
83% 1 
18 The definition of CRMS/CFSPID is an infant with a positive 
NBS test for CF and either:  
 A sweat chloride value less than 30 mmol/L and 2 CFTR 
mutations, at least 1 of which has unclear phenotypic 
consequences  
OR  
 An intermediate sweat chloride value (30-59 mmol/L) and 1 
or 0 CF-causing mutations 
86% 1 
19 Children designated as CRMS/CFSPID should undergo at least 
one repeat sweat chloride test at CF centers with suitable 
expertise, such as an accredited CF center. 
86% 1 
20 Children designated as CRMS/CFSPID should have clinical 
evaluation performed by CF providers to identify the minority 
that may develop clinical symptoms. 
83% 1 
21 Children designated as CRMS/CFSPID can be considered for 
extended CFTR gene analysis (sequencing and or deletion 
duplication testing), as well as CFTR functional analysis 
(NPD/ICM) testing to further define their likelihood of 
developing CF. 
80% 0 
22 The decision to reclassify children designated as 
CRMS/CFSPID as CF is an integrated decision that should take 
into account functional assessment of CFTR (sweat chloride, 
and possibly NPD/ICM), CFTR genetic analysis, and clinical 
assessment by the CF clinicians caring for the patient. 
90% 0 
23 Genetic counseling should be offered to families of individuals 
followed for CRMS/CFSPID, including a discussion of the risk 
in future pregnancies. 
100% 1 
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24 Research Recommendation: Infants with a designation of 
CRMS/CFSPID (by definition) do not have clinical features 
consistent with a diagnosis of CF and further research is needed 
to determine the prognosis and best practices for frequency and 
duration of follow up. 
96% 0 
25 For individuals presenting with CF symptoms, the same 
diagnostic criteria recommended for the screened population for 
sweat chloride testing, CFTR genetic analysis, and CFTR 
functional testing should be used to confirm a CF diagnosis. 
93% 0 
26 The diagnosis of CFTR-related disorder has been defined as a 
monosymptomatic clinical entity 
[CBAVD/pancreatitis/bronchiectasis] associated with CFTR 
dysfunction that does not fulfill the diagnostic criteria for CF.  
86% 2 
27 Clinicians should avoid the use of terms like classic/nonclassic 
CF, typical/atypical CF, delayed CF, since these terms have no 
harmonized definition and could be confusing for families or 
caregivers. 
83% 1 
  512 
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TABLE II. ICD-10 Codes for Use in Individuals with Cystic Fibrosis and other CFTR 513 
Dysfunctional Diseases or Disorders.  514 
Disease/Disorder Primary ICD-10 Code Secondary ICD-10 Code 
Cystic fibrosis, unspecified E84.9  
Cystic fibrosis, with meconium ileus E84.11  
Cystic fibrosis, with other intestinal manifestations 
(eg, distal intestinal obstruction syndrome (DIOS)) 
E84.19  
Cystic fibrosis, with pulmonary manifestations E84.0 Use secondary code for 
details such as infectious 
organisms present (eg, 
B96.5 for Pseudomonas 
aeruginosa) 
Cystic fibrosis, with acute pneumothorax E84.09 J93.83 
Cystic fibrosis, with pneumothorax not otherwise 
specified 
E84.09 J93.9 
Cystic fibrosis, with hemoptysis  E84.09 R04.2 
CRMS, metabolic disorder unspecified E88.89   
CFSPID P09 (abnormal findings on 
neonatal screening)* 
Or: 
E88.89 (if CRMS/CFSPID 
is adopted as the preferred 
terminology 
 
CFTR-related disorder 
(Code the signs/symptoms as described but do NOT 
use E84.9)  
 Pancreatitis, recurrent 
 CBAVD 
 Bronchiectasis, chronic acquired 
 
 
 
K85.9 
Q55.4**  
J47.9 
 
 
 
}  
 
 
 
 
Z14.1  
(Cystic fibrosis 
carrier status) 
*Describes positive newborn screen result with an inclusive diagnosis but only applies to the newborn period and 515 
thus cannot be used in follow-up care 516 
**Preferred over N46.025 (azoospermia due to a systemic disease) 517 
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 518 
Figure. Recommended Pathway for Diagnosis of Cystic Fibrosis. 519 
Notes: 520 
1. A positive newborn screen may include CFTR genetic analysis. (See also Addendum for J Pediatrics MS #4, 521 
which is being drafted.)  Even though the genetic analysis may be done first, to establish the diagnosis of CF, sweat 522 
chloride testing is the first test to be considered.  523 
2. Clinical symptoms refer to nonscreened patients. (See also Addendum for J Pediatrics MS #6.)  524 
3. Family history refers to a 1st degree relative with CF (parent, child, sibling).  525 
4. All individuals with a CF diagnosis should undergo genotyping.  526 
5. Rare individuals may have CF with a sweat chloride below the intermediate range.(19) CF may still be considered 527 
as a diagnosis if alternatives are excluded and other confirmatory tests (genotype, physiologic testing) support CF. 528 
(See also Addendum for J Pediatrics MS #3). 529 
6. CF-causing as defined by CFTR2 group.(19) For further details and discussion see Addendum for J Pediatrics MS 530 
#3.  531 
7. Genetic analysis that reveals CFTR variants, but cannot be classified as a CF-causing genotype. If genetic analysis 532 
is limited, and especially if only one CFTR variant is identified, further CFTR testing (such as sequencing, 533 
deletion/duplication detection) should be performed. (See also Addendum for J Pediatrics MS #3.)   534 
8. The absence of any CF-causing mutation, or mutation of varying clinical consequence (MVCC), or undefined 535 
CFTR variants makes CF unlikely. Variants that are known to be non-CF-causing are not considered to be CFTR 536 
variants for purposes of diagnosis. 537 
9. CF diagnosis not resolved is meant to consider alternative characterizations such as CRMS/CFSPID in the case of 538 
NBS; CFTR-related disorder in appropriate circumstances. In many instances no distinct label may be appropriate, 539 
but further follow-up may be warranted. In these cases, the use of “CF carrier” or the specific clinical problem 540 
should be used for characterization/labeling purposes.  541 
 542 
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ADDENDUM 1 787 
 788 
References to manuscripts being drafted for submission to The Journal of Pediatrics as part of 789 
the supplement entitled "Diagnosis of Cystic Fibrosis: Consensus Guidelines and Supporting 790 
Evidence from the Cystic Fibrosis Foundation 2015 Diagnosis Consensus Conference." (Titles 791 
and authorship may not be final; responsible authors are denoted in bold type.) 792 
 793 
MS # 1. Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation 794 
(this manuscript) 795 
 796 
MS # 2. Cystic Fibrosis Diagnostic Challenges over Four Decades: Historical Perspectives and 797 
Lessons Learned  798 
(P. Farrell, T. White, B. Rosenstein and N. Derichs) 799 
 800 
MS # 3. Applying CFTR Genetics and CFTR2 Data to Facilitate Diagnoses 801 
(P. Sosnay, C. Castellani and D. Salinas) 802 
 803 
MS # 4. Diagnosis of Cystic Fibrosis in Screened Populations 804 
(P. Farrell, T. White, M. Howenstine, A. Munck, R. Parad, M. Rosenfeld, O. Sommerberg, F. 805 
Accurso, and J. Davies) 806 
 807 
MS # 5. CFTR-Related Metabolic Syndrome and Cystic Fibrosis Screen Positive, Inconclusive 808 
Diagnosis 809 
(C. Ren, K. Southern, M. Howenstine, A. Munck, I. Sermet, and D. Borowitz) 810 
 811 
MS # 6. Diagnosis of Cystic Fibrosis in Nonscreened Populations 812 
(P. Sosnay, N. Derichs, and J. Nick) 813 
 814 
  815 
ADDENDUM 2 [revisions to the 2008 consensus guidelines for diagnosis]:  816 
 Sweat testing should be done in everyone, including all NBS+ infants 817 
 Sweat Cl normal threshold is 30 mmol/L for all ages 818 
 NPD/ICM should be done in a validated lab 819 
 Use the CFTR2 classification of CFTR mutations 820 
 CRMS=CFSPID  Harmonized definition 821 
 Presumptive Dx of CF can be made in NBS+/2 mutation infant 822 
 Non screened population with non-diagnostic sweat Cl 823 
o Extended genetic analysis 824 
o Ancillary testing NPD/ICM 825 
 CRMS/CFSPID 826 
o Repeat sweat testing up to 2 y/o 827 
o Extended genetic analysis is recommended 828 
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o Duration and frequency of follow up remains undetermined 829 
o Conversion to a CF Dx is a clinical decision 830 
 Other definitions 831 
o Avoid terms like “atypical” or “nonclassical” CF since there is no consensus 832 
definition of these terms 833 
o CFTR Related Disorder: A monosymptomatic entity that does not meet diagnostic 834 
criteria for CF 835 
